Patient Access

Eversana senior vice president of health innovation, Alberta Spreafico, discusses the company's collaboration with the Digital Therapeutics Alliance to analyze frameworks and map reimbursement pathways in Europe for digital health adoption.

The vision-restoring device will be implanted in humans within six to 12 months, following a successful monkey implantation that has remained active for three years, Musk said.

In March, the company received FDA marketing authorization for the first at-home test to detect chlamydia, gonorrhea and trichomoniasis.

The company's valuation has increased by $1 billion since its $130 million Series E funding round last year.

Also, radiology reporting solutions provider Kailo Medical has acquired a clinician-founded genAI company.

Also, VUNO has obtained regulatory clearance in South Korea for its AI-based screening solution for kidney failure.

The company will use the funds to grow the company, increase manufacturing operations and put in place more products in the research and development pipeline.  

The two organizations will collaborate to accelerate the company's growth and enhance proactive care and management of chronic diseases.

Manulife Group Benefits plan members will have virtual access to Maven's digital platform, connecting them to a global network of providers.

The partners will develop and clinically validate an AI tool that integrates into EHRs to accelerate the diagnosis of hypophosphatasia, a rare genetic bone disorder.